The identification and reporting of adverse drug reactions (ADRs) is essential to ensure safe and effective medication use. Despite ongoing pharmacologic advances, healthcare professionals continue to be hindered by barriers that include a lack of true consensus on both the definition and the value of reporting ADRs. This program is intended to identify the barriers of ADR reporting and to support the development of a consensus and recognized shared value of reporting these events to the entire medication safety community.
